Henne, Sergej

[["dc.bibliographiccitation.firstpage","767"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Antimicrobial Agents and Chemotherapy"],["dc.bibliographiccitation.lastpage","770"],["dc.bibliographiccitation.volume","44"],["dc.contributor.author","Smirnov, Alexey"],["dc.contributor.author","Wellmer, A."],["dc.contributor.author","Gerber, Joachim"],["dc.contributor.author","Maier, K."],["dc.contributor.author","Henne, S."],["dc.contributor.author","Nau, R."],["dc.date.accessioned","2018-11-07T08:56:14Z"],["dc.date.available","2018-11-07T08:56:14Z"],["dc.date.issued","2000"],["dc.description.abstract","In a rabbit model of Streptococcus pneumoniae meningitis, 5 mg of gemifloxacin mesylate (SB-265805) per kg/h reduced the bacterial titers in cerebrospinal fluid (CSF) almost as rapidly as 10 mg of ceftriaxone per kg/h (Delta log CFU/ml/h +/- standard deviation [SD], -0.25 +/- 0.09 versus -0.38 +/- 0.11; serum and CSF concentrations of gemifloxacin were 2.1 +/- 1.4 mg/liter and 0.59 +/- 0.38 mg/liter, respectively, at 24 h). Coadministration of 1 mg of dexamethasone per kg did not affect gemifloxacin serum and CSF levels (2.7 +/- 1.4 mg/liter and 0.75 +/- 0.34 mg/liter, respectively, at 24 h) or activity (Delta log CFU/ml/h +/- SD, -0.26 +/- 0.11)."],["dc.identifier.doi","10.1128/AAC.44.3.767-770.2000"],["dc.identifier.isi","000085399200049"],["dc.identifier.pmid","10681354"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23091"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Microbiology"],["dc.relation.issn","0066-4804"],["dc.title","Gemifloxacin is effective in experimental pneumococcal meningitis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]